Product Description
orally active novel chymase inhibitor
Mechanisms of Action: Chymase Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Daiichi Sankyo
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01756898 |
ASBI 704 | P2 |
Completed |
Dermatitis, Atopic |
2014-01-14 |
2024-02-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|